Immune-targeted combo with chemo for ambiguous leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of immune-targeted therapy plus chemotherapy for people with a rare type of leukemia that doesn't clearly fit into the usual categories. The goal is to see if this approach can help control the leukemia better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of leukemia that doctors aren't sure if it's from myeloid or lymphoid cells (called acute leukemia of ambiguous lineage).
- You are 14 years old or older.
- You are able to do most of your daily activities without help (ECOG score 0–2).
- Your liver, kidney, heart, and pancreas are working well enough based on recent blood tests and an echocardiogram.
- You are not pregnant or nursing, and you do not have another active cancer, HIV, or a serious uncontrolled medical condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
Hear when a new Adult ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.